TY - JOUR T1 - NSC 290205-based Therapy in Murine Pancreatic Adenocarcinoma PAN02 in Combination with Adriamycin (ADR) JF - Anticancer Research JO - Anticancer Res SP - 243 LP - 247 VL - 26 IS - 1A AU - ATHANASIOS PAPAGEORGIOU AU - CHARALAMBOS ANDREADIS AU - ANASTASIOS BOUTIS AU - THEODOROS S. LIALIARIS AU - DESPINA MOURATIDOU Y1 - 2006/01/01 UR - http://ar.iiarjournals.org/content/26/1A/243.abstract N2 - Background: NSC 290205 (A) is a hybrid synthetic antitumor ester, which combines a D-lactam derivative of androsterone and nitrogen mustard. In this study, the antitumor activity of A in combination with ADR (AHOP) was investigated in comparison with the standard CHOP regimen. Materials and Methods: PAN02 adenocarcinoma was used in this study. C57Bl mice were used for chemotherapy evaluation. The activity was assessed from the inhibition of tumor growth and the oncostatic parameter T/C%. Results: Treatment with A or cyclophosphamide produced almost equal borderline activity. Moreover, both the CHOP and AHOP regimens showed significant and comparable antitumor effects. AHOP caused the maximum effect, inhibiting tumor growth by 56.8%. CHOP was less effective, producing 47.7% tumor inhibition. Conclusion: It is very likely that the D-lactamic steroid (androstan) alkylator for A, containing the amide group -NH-CO-, combined with ADR which intercalates between DNA base-pairs, is the explanation for the higher activity of AHOP as compared to CHOP. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -